{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:37Z","timestamp":1793291497226,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejmg.2024.104958","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T12:13:33Z","timestamp":1719663213000},"page":"104958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5087","authenticated-orcid":false,"given":"Giampiero I.","family":"Baroncelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Pelosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Toschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Comberiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2024.104958_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00774-020-01136-8","article-title":"Pulp chamber features, prevalence of abscesses, disease severity, and phex mutation in X-linked hypophosphatemic rickets","volume":"39","author":"Baroncelli","year":"2021","journal-title":"J. Bone Miner. Metabol."},{"key":"10.1016\/j.ejmg.2024.104958_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40618-023-02202-4","article-title":"Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X\u2010linked hypophosphatemic rickets","volume":"47","author":"Baroncelli","year":"2024","journal-title":"J. Endocxrinol. Invest."},{"key":"10.1016\/j.ejmg.2024.104958_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in Southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmg.2024.104958_bib6","author":"Bellamy"},{"key":"10.1016\/j.ejmg.2024.104958_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","article-title":"Efficacy of burosumab in adults with x\u2010linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double\u2010blind placebo\u2010controlled phase 3 study","volume":"111","author":"Brandi","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ejmg.2024.104958_bib8","first-page":"1701","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejmg.2024.104958_bib9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2024.104958_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmg.2024.104958_bib11","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmg.2024.104958_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/adc.73.1.17","article-title":"Cross sectional stature and weight reference curves for the UK, 1990","volume":"73","author":"Freeman","year":"1995","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmg.2024.104958_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jpain.2021.04.018","article-title":"A mediation appraisal of catastrophizing, pain-related outcomes, and race in adults with knee osteoarthritis","volume":"22","author":"Fullwood","year":"2021","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmg.2024.104958_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11914-021-00669-9","article-title":"Burosumab for pediatric X-linked hypophosphatemia","volume":"19","author":"Imel","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.ejmg.2024.104958_bib15","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmg.2024.104958_bib16","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmg.2024.104958_bib17","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","article-title":"Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level","volume":"108","author":"Imel","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmg.2024.104958_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002676","article-title":"Benefit of burosumab in adults with X- linked hypophosphataemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenicky","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ejmg.2024.104958_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmg.2024.104958_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.866170","article-title":"Persistent lower limb deformities despite amelioration of rickets in X-linked hypophosphatemia (XLH). A prospective observational study","volume":"13","author":"Mindler","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1034580","article-title":"Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries","volume":"13","author":"Mughal","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib22","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0564","article-title":"Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration","volume":"11","author":"Nguyen","year":"2022","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ejmg.2024.104958_bib23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient\u2010reported outcomes from a randomized, active\u2010controlled, open\u2010label, phase 3 trial of burosumab versus conventional therapy in children with X\u2010linked hypophosphatemia","volume":"108","author":"Padidela","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ejmg.2024.104958_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X\u2010linked hypophosphatemia: results from a 24\u2010week treatment continuation period after a 24\u2010week double\u2010blind placebo\u2010controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ejmg.2024.104958_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib26","first-page":"48","article-title":"Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Ramos","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104958_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.ejmg.2024.104958_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000184216","article-title":"Direct measurement of TP\/GFR: a simple and reliable parameter of renal phosphate handling","volume":"44","author":"Stark","year":"1986","journal-title":"Nephron"},{"key":"10.1016\/j.ejmg.2024.104958_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","article-title":"Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score","volume":"122","author":"Thacher","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.ejmg.2024.104958_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/j.pain.0000000000001758","article-title":"Graded chronic pain scale revised: mild, bothersome, and high impact chronic pain","volume":"161","author":"Von Korff","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ejmg.2024.104958_bib31","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmg.2024.104958_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721224000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721224000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T03:41:42Z","timestamp":1722224502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721224000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":32,"alternative-id":["S1769721224000508"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2024.104958","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2024.104958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104958"}}